Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 12 art units • 17 examiners • 0 of 19 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Lonza Ltd. has 21 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 19 examiners across 14 art units, reflecting a distributed portfolio with some repeated examiner and art-unit assignments. TRAN, CHRISTINA L is the busiest examiner, with 3 pending matters.
The three matters before TRAN, CHRISTINA L offer a practical point for coordinated prosecution review. The broader portfolio still requires distributed management because many matters are assigned to other examiners and art units. Counsel should separate examiner-specific tactics from recurring biotechnology issues that may appear across records.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 7 (37%) |
| Double-patenting + other | 5 (26%) |
| Multi-statute (no §101) | 6 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 3 | 51.6% | +49.8% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| KIPOUROS, HOLLY MICHAELA | 1 | 69.8% | +21.3% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | ALLEN, SARAH ELIZABETH | 47d |
| 17768610 | End-to-End Platform for Human Pluripotent Stem Cell Manufacturing | ROGERS, ERIC JASON | 49d |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | — |
| 18769485 | Midscale Model For Organic Growth and Phasing | KIPOUROS, HOLLY MICHAELA | — |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | — |
| 18245687 | HOST CELLS OVEREXPRESSING TRANSLATIONAL FACTORS | HOLLAND, PAUL J | — |
| 18552778 | EXTRACELLULAR VESICLE COMPOSITIONS | MCKILLOP, JOHN CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 7d |
| 17768610 | End-to-End Platform for Human Pluripotent Stem Cell Manufacturing | ROGERS, ERIC JASON | 49d |
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | WESTON, ALYSSA G | — |
| 18300994 | METHODS FOR NUCLEAR REPROGRAMMING USING SYNTHETIC TRANSCRIPTION FACTORS | MCCORMICK, CATHERINE LYNN | — |
| 18063982 | METHODS FOR PRODUCING IMMUNE CELL CULTURES | VANHORN, ABIGAIL LOUISE | — |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | — |
| 18769485 | Midscale Model For Organic Growth and Phasing | KIPOUROS, HOLLY MICHAELA | — |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1637 | 5 |
| 1633 | 2 |
| 1638 | 2 |
| 1652 | 2 |
| 1636 | 1 |
| 1799 | 1 |
| 1631 | 1 |
| 1656 | 1 |
| 1693 | 1 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | WESTON, ALYSSA G | 1633 | §103§112DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18300994 | METHODS FOR NUCLEAR REPROGRAMMING USING SYNTHETIC TRANSCRIPTION FACTORS | MCCORMICK, CATHERINE LYNN | 1638 | §103Other | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18063982 | METHODS FOR PRODUCING IMMUNE CELL CULTURES | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | — | Pending | Dec 09, 2022 |
| 17768610 | End-to-End Platform for Human Pluripotent Stem Cell Manufacturing | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 49d | Pending | Apr 13, 2022 |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18769485 | Midscale Model For Organic Growth and Phasing | KIPOUROS, HOLLY MICHAELA | 1799 | §102§112 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | 1631 | §101§102§103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18454930 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | MEAH, MOHAMMAD Y | 1652 | §103§112DP | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18245687 | HOST CELLS OVEREXPRESSING TRANSLATIONAL FACTORS | HOLLAND, PAUL J | 1656 | §103§112 | Final Rejection | — | Pending | Mar 16, 2023 |
| 17776932 | METHODS OF CELL SELECTION | LEVIN, JOEL D | 1633 | §103 | Final Rejection | 29d | Pending | May 13, 2022 |
| 17434442 | Purification Process for Biological Molecules Such as Plasmid DNA Using Anionic Exchange Chromatography | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | — | Pending | Aug 27, 2021 |
| 18552778 | EXTRACELLULAR VESICLE COMPOSITIONS | MCKILLOP, JOHN CHARLES | 1637 | §103§112 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18246312 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | ROYCE, LIAM A | 1777 | §103 | Final Rejection | 7d | Pending | Mar 22, 2023 |
| 18246301 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | BREWSTER, HAYDEN R | 1779 | §103 | Final Rejection | 44d overdue | Pending | Mar 22, 2023 |
| 18050017 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 1637 | §103DP | Non-Final OA | — | Pending | Oct 26, 2022 |
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112 | Non-Final OA | 47d | Pending | Feb 14, 2022 |
| 17635315 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Feb 14, 2022 |
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 1637 | §103§112DP | Final Rejection | 7d | Pending | Feb 14, 2022 |
| 17293833 | ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112DP | Final Rejection | 13d | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLonza Ltd. has 19 pending office actions as of October 2026, spread across 12 art units and 17 examiners.
Christina L Tran has the most, with 3 of Lonza Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
